Biomarker hub
BRCA2
Trials and papers mentioning BRCA2.
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
RECRUITING · Phase not listed
Blood Markers of Early Pancreas Cancer
RECRUITING · Phase not listed
FTT PET/CT in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase not listed
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase not listed
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
RECRUITING · Phase not listed
Cell-free DNA in Hereditary And High-Risk Malignancies 1
ACTIVE_NOT_RECRUITING · Phase not listed
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
ACTIVE_NOT_RECRUITING · Phase not listed
Olaparib In Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
RECRUITING · Phase not listed
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
RECRUITING · Phase not listed
Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction
NOT_YET_RECRUITING · Phase not listed
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING · Phase not listed
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
RECRUITING · Phase not listed
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
ACTIVE_NOT_RECRUITING · Phase not listed
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
COMPLETED · Phase not listed
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
ACTIVE_NOT_RECRUITING · Phase not listed
Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study
NOT_YET_RECRUITING · Phase not listed
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
TERMINATED · Phase not listed
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
TERMINATED · Phase not listed
Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.
ACS medicinal chemistry letters · 2/12/2026
Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendations
genetic and genomic medicine · 2/25/2025
From genetic risk to early detection - clinical outcomes of a person-centered screening program for women with a high genetic risk of breast cancer.
Frontiers in oncology · 1/1/2025